Artelo Biosciences Inc
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a coc… Read more
Artelo Biosciences Inc (ARTL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 3.342x
Based on the latest financial reports, Artelo Biosciences Inc (ARTL) has a cash flow conversion efficiency ratio of 3.342x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.25 Million) by net assets ($-1.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Artelo Biosciences Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Artelo Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Artelo Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Artelo Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MK Trend Co. Ltd.
KO:069640
|
-0.361x |
|
ODIGMA CONSULTANCY SOLUTIONS LTD
NSE:ODIGMA
|
N/A |
|
Arshiya Limited
NSE:ARSHIYA
|
-0.030x |
|
Nepa AB
ST:NEPA
|
-0.412x |
|
Cannabis Sativa Inc
OTCQB:CBDS
|
0.956x |
|
Kakatiya Cement Sugar & Industries Limited
NSE:KAKATCEM
|
0.019x |
|
Great Atlantic Resources Corp
V:GR
|
0.096x |
|
Complii Fintech Solutions Ltd
AU:CF1
|
-0.119x |
Annual Cash Flow Conversion Efficiency for Artelo Biosciences Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Artelo Biosciences Inc from 2014 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-1.27 Million | $-8.52 Million | 6.698x | +329.18% |
| 2024-12-31 | $2.86 Million | $-8.35 Million | -2.923x | -318.51% |
| 2023-12-31 | $11.75 Million | $-8.21 Million | -0.698x | -69.21% |
| 2022-12-31 | $19.40 Million | $-8.01 Million | -0.413x | +19.07% |
| 2021-12-31 | $12.04 Million | $-6.14 Million | -0.510x | +54.55% |
| 2020-12-31 | $3.87 Million | $-4.35 Million | -1.122x | -119.41% |
| 2019-12-31 | $5.46 Million | $-2.79 Million | -0.511x | -104.29% |
| 2018-12-31 | $-134.97K | $-1.61 Million | 11.928x | +3097.41% |
| 2017-12-31 | $544.84K | $-216.82K | -0.398x | -129.70% |
| 2016-12-31 | $-13.80K | $-18.49K | 1.340x | +251.72% |
| 2015-12-31 | $15.29K | $-13.50K | -0.883x | -70.39% |
| 2014-12-31 | $29.46K | $-15.27K | -0.518x | -- |